Evidence map›Paper›PMID 34890627›Full record

ArticleThe Journal of investigative dermatology2022

miR-181a Promotes Multiple Protumorigenic Functions by Targeting TGFβR3.

Vida Chitsazzadeh, Tran N Nguyen, Alvaro de Mingo Pulido, Bruna B Bittencourt, Lili Du, Charles H Adelmann, Ivannie Ortiz Rivera, Kimberly A Nguyen, Leah D Guerra, Andrew Davis and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of investigative dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Role of miR‑181a‑5p in cancer (Review).International journal of oncology · 2023
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Vida ChitsazzadehDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Tran N NguyenDepartment of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
Alvaro de Mingo PulidoDepartment of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
Bruna B BittencourtDepartment of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
Lili DuDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Charles H AdelmannDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ivannie Ortiz RiveraDepartment of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
Kimberly A NguyenDepartment of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
Leah D GuerraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Andrew DavisDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
Marco NapoliDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
Wencai MaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Richard Eric DavisDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Kimal RajapaksheDepartment of Molecular Biology, Baylor College of Medicine, Houston, Texas, USA.
Cristian CoarfaDepartment of Molecular Biology, Baylor College of Medicine, Houston, Texas, USA.
Elsa R FloresDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
Kenneth Y TsaiDepartment of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA; Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA. Electronic address: Kenneth.Tsai@moffitt.org.
Moffitt Cancer Center · USThe University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5M
Identification of non-coding RNAs to therapeutically target undruggable pathways in metastatic lung adenocarcinoma and squamous cell carcinomaR35CA197452 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FLORES, ELSA R · 2016 to 2022
$6.4M
(PQA4) Molecularly Targeted Chemoprevention for Preneoplastic Squamous EpitheliaR01CA194617 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI TSAI, KENNETH Y · 2015 to 2018
$1.7M
MicroRNA Targets for Chemoprevention of Squamous Cell Carcinoma (R01 CA194062-01A1)R01CA194062 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI TSAI, KENNETH Y · 2016 to 2020
$1.6M
NCI NIH HHS P30 CA076292NCI NIH HHS R01 CA194062NCI NIH HHS R01 CA194617NCI NIH HHS R35 CA197452
6 · The paper itself

Abstract

Cutaneous squamous cell carcinoma (cSCC) comprises 15‒20% of all skin cancers and has a well-defined progression sequence from precancerous actinic keratosis to invasive cSCC. To identify targets for chemoprevention, we previously reported a cross-species analysis to identify the transcriptional drivers of cSCC development and identified miR-181a as a potential oncomiR. We show that the upregulation of miR-181a promotes multiple protumorigenic properties by targeting an understudied component of TGFβ signaling, TGFβR3. miR-181a and TGFβR3 are upregulated and downregulated, respectively, in cSCC. miR-181a overexpression (OE) and TGFβR3 knockdown (KD) significantly suppresses UV-induced apoptosis in HaCaT cells and in primary normal human epidermal keratinocytes. In addition, OE of miR-181a or KD of TGFβR3 by short hairpin RNA enhances anchorage-independent survival. miR-181a OE or TGFβR3 KD enhances cellular migration and invasion and upregulation of epithelial‒mesenchymal transition markers. Luciferase reporter assays demonstrate that miR-181a directly targets the 3'-untranslated region of TGFβR3. miR-181a upregulates phosphorylated SMAD3 levels after TGFβ2 administration and results in elevated SNAIL and SLUG expression. Finally, we confirm in vivo that miR-181a inhibition compromises tumor growth. Importantly, these phenotypes can be reversed with TGFβR3 OE or KD in the context of miR-181a OE or KD, respectively, further highlighting the physiologic relevance of this regulation in cSCC.

Indexed as

Carcinoma, Squamous CellMicroRNAsProteoglycansReceptors, Transforming Growth Factor betaSkin Neoplasms3' Untranslated RegionsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumans3' Untranslated RegionsbetaglycanMicroRNAsMIrn181 microRNA, humanProteoglycansReceptors, Transforming Growth Factor beta

Identifiers

PMID34890627
PMCPMC9174350
OpenAlexW4200538411

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.